2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3529 Serial spatial profiling reveals compartment‑specific T‑regulatory cell depletion and skin disease control in mycosis fungoides with low‑dose total skin electron beam therapy plus brentuximab vedotin.

Bouthaina S. Dabaja, MD, Michael Spiotto, MD2, Auris O. Huen, MD, PharmD3, Daniela Duenas4, Jillian R. Gunther, MD PhD5, Julia Dai, MD6, Francisco Rodolfo Saenz, PhD7, Chelsea C. Pinnix, MD, PhD8, Ranjit Nair, MD9, Seoung Ae Lee10, Klaudia Szymonowicz11, Chris Pearlnath12, Nathan Comeaux13, Susan Y. Wu, MD14, Penny Q. Fang15, Timothy A. Lin, MD16, Samer A Srour, MB ChB, MS17, Jeremy Ramdial, MD18, Yago Nieto, MD, Ph.D19, Sattva S Neelapu Sr, MD20, Omran Saifi, MD21, Shryll Turner, APRN22, Travis Rougeau, BS23, Luis Malpica, MD24, Luis E. Fayad, MD25, Chitra Hosing, MD26, Cara Haymaker27, Swaminathan P. Iyer, MD28
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 UT MD Anderson Cancer Center, Houston, Texas, United States
8 UT MD Anderson Cancer Center, Houston, Texas, United States
9 UT MD Anderson Cancer Center, Houston, Texas, United States
10 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 UT MD Anderson Cancer Center, Houston, Texas, United States
13 UT MD Anderson Cancer Center, Houston, Texas, United States
14 UT MD Anderson Cancer Center, Houston, Texas, United States
15 UT MD Anderson Cancer Center, Houston, Texas, United States
16 UT MD Anderson Cancer Center, Houston, Texas, United States
17 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 UT MD Anderson Cancer Center, Houston, Texas, United States
21 UT MD Anderson Cancer Center, Houston, Texas, United States
22 UT MD Anderson Cancer Center, Houston, Texas, United States
23 UT MD Anderson Cancer Center, Houston, Texas, United States
24 UT MD Anderson Cancer Center, Houston, Texas, United States
25 UT MD Anderson Cancer Center, Houston, Texas, United States
26 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 UT MD Anderson Cancer Center, Houston, Texas, United States

Introduction: Mycosis Fungoides (MF) remains largely incurable; treatments including but not limited to Total Skin Electron Beam Therapy (TSEBT) and or Brentuximab Vedotin (BV) yield high response rates yet frequent relapse. Given the immunomodulatory effects of radiation, we hypothesize that low‑dose TSEBT “resets” the MF microenvironment and intermittent, reduced‑dose BV sustains this remodeling to extend remission duration and time to next therapy (TTNT). A prospective, single-arm phase II trial (NCT05357794 ) is currently enrolling patients with stage IB-IV MF. Safety run-in results, preliminary efficacy data, and correlative findings will be presented.

Methods: Treatment consists of ultra‑low‑dose total skin electron beam therapy (TSEBT; 5 cycles every 3 months: 8 Gy in cycle 1, then 4 Gy in cycles 2–5) combined with reduced‑dose brentuximab vedotin (BV; 0.9 mg/kg every 3 weeks for 12 months), initiated 1 week after the first TSEBT cycle to minimize neuropathy while maintaining disease control. The primary endpoint is time to next therapy (TTNT); secondary endpoints include ORR, CR, duration of response, PFS, pruritus/quality of life, and safety. This report focuses on the exploratory endpoints portion of the study, assessing tumor microenvironment remodeling using serial skin biopsies obtained pre‑TSEBT, post‑TSEBT, and during BV. In this interim analysis, core biopsies were obtained from the same lesion at Pre‑RT (n=6), Post‑RT/pre‑BV (n=5), and Post‑BV prior to cycle 2 (n=3). Ultrahigh‑plex imaging was performed using PhenoCycler‑Fusion with a 35‑marker panel resolving T-cell lineage and MF phenotype (CD3, CD4, CD8, CD2, CD5), the BV target (CD30), immunoregulation and exhaustion (FOXP3, PD-1, TIM-3, PD-L1, ICOS), cytotoxic and innate effectors (granzyme A/B, TIA-1, EOMES, CD56, CD57), myeloid subsets (CD68, CD163, CD14, CD11b, HLA-DR, CSF-1R), and proliferation (Ki-67). Epidermis and dermis were segmented separately using HALO AI to account for epidermotropism and differential TSEBT dose. Groups were compared using Kruskal–Wallis with Mann–Whitney U for pairwise tests, and correlations were assessed with Spearman; p values are exploratory and unadjusted.

Results: In the first six patients enrolled, low‑dose TSEBT plus reduced‑dose BV produced marked, compartment‑specific T‑cell reduction that correlated with cutaneous disease control. Epidermal CD3+ density dropped after RT (median 616 to 48 cells/mm2, p=0.003), leaving only 3–56 T cells per sample, with no further change after BV  (p=0.79) in the only 3 patients examined; dermal density declined progressively across all three timepoints (3864 to 992 to 66 cells/mm2, p=0.026). The decline was cytoreductive rather than redistributive: the dermal Ki-67+ CD3+ fraction declined from 17.5% pre-RT to 11.2% post-RT to 1.0% post-BV (p=0.028). Residual malignant cells (CD3+CD4+CD8-) were detectable at Post-BV in all three patients who reached that timepoint, but the depth of clearance varied markedly and mirrored the CD3+ pattern: dermal malignant density in the patient who relapsed in the skin (patient 2) fell only to 21% of baseline, with epidermal malignant density essentially unchanged, versus 3% and 0.6% in the two whose skin cleared (patients 3 and 6; residual 10 and 38 cells/mm2, respectively). Malignant cells still comprised 40-57% of the residual dermal CD3+ compartment, indicating proportional clearance. The one patient withdrawn for early relapse (patient 1) showed no dermal depletion (2399 to 2900 cells/mm2). Epidermal Tregs fell from a median 22 to 3 to 0 cells/mm2 (p=0.027) and dermal Tregs declined from 126 to 86 to 18 cells/mm2. Dermal CD57+ NK cells were modestly higher after RT, while EOMES+ cells and CD3-CD56+ NK cells did not change significantly. Myeloid compartments were largely stable: dermal CD14+ monocytes showed a transient post-RT rise without sustained direction (131, 268, 44 cells/mm2; p=0.05) and CD68+ macrophage density was not significantly changed (p=0.86).

Conclusions: Low-dose TSEBT combined with reduced-dose BV produced compartment-specific T-cell depletion, including higher NK cell activation and higher reduction of regulatory T cell subsets, indicating true cytoreduction. Depth of dermal depletion tracked cutaneous disease control, suggesting that residual dermal T-cell density may serve as a candidate correlative biomarker of skin response. Confirmation in the full cohort, with correlation is ongoing

Bouthaina S. Dabaja, MD: No relevant conflicts of interest to declare.